Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on July 26, 2012, with the earliest event reported on that date. The filing details significant capital market activities, including the entry into a new credit facility agreement and the issuance of senior notes.
Key Financial Metrics and Capital Structure
- New Credit Facility: Entered into a $1.5 billion Five Year Competitive Advance and Revolving Credit Facility Agreement on July 30, 2012.
- Existing Facility Status: The Company had an existing $1.5 billion facility established in September 2011 with no borrowings outstanding as of June 30, 2012.
- Debt Issuance: Agreed to sell $2.0 billion in aggregate principal amount of senior notes:
- $750 million of 0.875% notes due 2017.
- $750 million of 2.000% notes due 2022.
- $500 million of 3.250% notes due 2042.
- Closing Date: The sale of the notes closed on July 31, 2012.
Material Changes and Covenants
The new credit facility agreement includes customary negative covenants limiting consolidations, mergers, asset sales, incurrence of liens, and sale-leaseback transactions. It also requires the maintenance of a long-term debt rating from a specific credit rating agency. Notably, the agreement contains no financial covenants. Events of default include nonpayment, covenant violations, breaches of debt agreements exceeding $100 million, bankruptcy, judgments exceeding $100 million, or a change in control.
Outlook, Risks, and Management Commentary
The filing does not provide specific management commentary on future business outlook, revenue guidance, or operational risks beyond the standard legal provisions of the debt agreements. The primary focus is on the execution of the financing transactions and the legal validity of the notes, supported by an opinion from Kirkland & Ellis LLP.
Investor Verification Checklist
- Verify the final closing of the $2.0 billion note issuance on July 31, 2012.
- Confirm the terms of the new $1.5 billion revolving credit facility, specifically the absence of financial covenants.
- Review the Sixth Supplemental Indenture (Exhibit 4.1) for specific terms regarding the new notes.
- Monitor the Company's long-term debt rating to ensure compliance with the new facility's affirmative covenants.